Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Should radiotherapy be succeed tumorectomy in patients with low risk ductal carcinoma in situ (DCIS) when using Van Nuys Prognostic Index based treatment?

Sub-category:
Adjuvant Therapy

Category:
Breast Cancer—Local/Regional/Adjuvant

Meeting:
2018 ASCO Annual Meeting

Abstract No:
e12561

Citation:
J Clin Oncol 36, 2018 (suppl; abstr e12561)

Author(s): Anna Niwinska, Jacek Galecki, Agnieszka Irena Jagiello-Gruszfeld; Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; The M.Sklodowska-Curie Memorial Cancer Center and Institute, Warsaw, Poland; The Maria Sklodowska-Curie Memorial Cancer Centre and Institute, Warsaw, Poland

Abstract Disclosures

Abstract:

Background: Selecting patients with low risk DCIS in whom radiotherapy could be safely omitted is still debatable. The Van Nuys Prognostic Index (VNPI) which analyses 4 prognostic factors helps in choosing such subgroup (VNPI score 4-6), neverthless its value is questionable. The aim of study: assess the role of radiotherapy after tumorectomy in patients with low risk DCIS based on VNPI. Methods: 737 consecutive breast DCIS patients were treated at a Cancer Center during 1999-2011 where tumorectomy (T), tumorectomy and radiotherapy (BCT) and mastectomy (M) were respectively performed in 21%, 32% and 47%. The competing risk of recurrence (RR) was investigated in each of these groups. The VNPI scores were then counted retrospectively. In the low risk group of patients with VNPI scores of 4-6, the RR was compared between those treated only with tumorectomy and with BCT. Cox multivariate analysis assessed the effect of radiotherapy on RR. Results: The 10-year RR of T, BCT and M treated patients were respectively 25%, 12% and 2.5% whereas after 15 years it respectively became 28%, 24% and 3%. In patients with VNPI scores of 4,5 and 6 treated with T and BCT, the competing RR at 10 years was respectively 22% and 2%. Cox multivariate analysis confirmed that radiotherapy decreased the local RR by a factor of 3 in patients with DCIS (HR 0.311). Conclusions: Patients scoring 4-6 VNPI points treated only with T showed a high risk of recurrence which constantly grew during 15 years of observation. Radiotherapy decreases the risk of RR even in this low risk group. Such patients should be informed about the local RR and should take part in radiotherapy treatment decision -making. New biological markers are thus needed to more precisely assess RR in DCIS patients.

 
Other Abstracts in this Sub-Category:

 

1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Meeting: 2018 ASCO Annual Meeting Abstract No: LBA1 First Author: Joseph A. Sparano
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

2. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 500 First Author: Michael Gnant
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

3. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 501 First Author: Robert E. Coleman
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

More...